First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment

Ozaras R., Mete B., Ceylan B., Ozgunes N., Gunduz A., Karaosmanoglu H., ...Daha Fazla

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.26, sa.7, ss.774-780, 2014 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 7
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1097/meg.0000000000000099
  • Dergi Adı: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.774-780
  • Anahtar Kelimeler: chronic hepatitis B, entecavir, tenofovir, treatment, VIRUS INFECTION, HEPATOCELLULAR-CARCINOMA, ANTIVIRAL THERAPY, NATURAL-HISTORY, VIRAL LOAD, LAMIVUDINE, UPDATE, RISK, PROGRESSION, MANAGEMENT
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background Hepatitis B virus (HBV) infection is a health problem worldwide. Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons. Tenofovir and entecavir are much more commonly used as they have better efficacy, tolerability, and high genetic barriers to resistance.